| Q43435091 | Association between 25-OH vitamin D and insulin is independent of lipoatrophy in HIV. |
| Q58704311 | Association between Mycobacterium avium complex lung disease and serum vitamin D status, antimicrobial peptide levels, and bone mineral density |
| Q40874258 | Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV. |
| Q35154069 | Change in vitamin d levels occurs early after antiretroviral therapy initiation and depends on treatment regimen in resource-limited settings |
| Q38973122 | Changes in bone turnover markers with HIV seroconversion and ART initiation |
| Q34340891 | Cholecalciferol supplementation in HIV-infected youth with vitamin D insufficiency: effects on vitamin D status and T-cell phenotype: a randomized controlled trial. |
| Q44094485 | Cholesterol, vitamin D and cardiovascular prevention in HIV patients treated with antiretroviral therapy |
| Q37855310 | Complications of HIV infection in an ageing population: challenges in managing older patients on long-term combination antiretroviral therapy. |
| Q37091552 | Contribution of Genetic Background and Clinical Risk Factors to Low-Trauma Fractures in Human Immunodeficiency Virus (HIV)-Positive Persons: The Swiss HIV Cohort Study. |
| Q36218302 | Corticosteroid therapy, vitamin D status, and inflammatory cytokine profile in the HIV-tuberculosis immune reconstitution inflammatory syndrome |
| Q40146615 | Counter-intuitive plasma vitamin D and zinc status in HIV-1-infected adults with persistent low-level viraemia after treatment initiation: a pilot case-control study. |
| Q36736469 | Cross-sectional study of vitamin D levels, immunologic and virologic outcomes in HIV-infected adults. |
| Q61798245 | Daily Nutritional Supplementation with Vitamin D₃ and Phenylbutyrate to Treatment-Naïve HIV Patients Tested in a Randomized Placebo-Controlled Trial |
| Q34403352 | Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen |
| Q34570942 | Determination of optimal vitamin D3 dosing regimens in HIV-infected paediatric patients using a population pharmacokinetic approach |
| Q42230910 | Different strategies of 25OH vitamin D supplementation in HIV-positive subjects |
| Q40671853 | Disrupted trabecular bone micro-architecture in middle-aged male HIV-infected treated patients. |
| Q64121483 | Effects of highly active antiretroviral therapy on semen parameters of a cohort of 770 HIV-1 infected men |
| Q43567346 | Fibroblast growth factor 23 in hypophosphataemic HIV-positive adults on tenofovir |
| Q36783435 | HIV-1 infection and antiretroviral therapies: risk factors for osteoporosis and bone fracture |
| Q39673591 | High prevalence of vitamin D deficiency in HIV-infected adults: what are the future research questions? |
| Q34799320 | High-dose vitamin D3 supplementation in children and young adults with HIV: a randomized, placebo-controlled trial |
| Q46543775 | Higher vitamin D levels in HIV-infected out-patients on treatment with boosted protease inhibitor monotherapy |
| Q34174790 | Hormonally active vitamin D3 (1alpha,25-dihydroxycholecalciferol) triggers autophagy in human macrophages that inhibits HIV-1 infection |
| Q36177899 | Hyperparathyroidism and complications associated with vitamin D deficiency in HIV-infected adults in New York City, New York. |
| Q45880333 | Hypovitaminosis D and osteopenia/osteoporosis in a haemophilia population: a study in HCV/HIV or HCV infected patients. |
| Q64285229 | Hypovitaminosis D in Hiv-Infected Patients |
| Q45024589 | Impact of vitamin D insufficiency on insulin homeostasis and beta cell function in nondiabetic male HIV-infected patients. |
| Q42287184 | Long-term HIV infection and antiretroviral therapy are associated with bone microstructure alterations in premenopausal women |
| Q55492735 | People Living With HIV: Implications for Rehabilitation Nurses. |
| Q33643157 | Per oral substitution with 300000 IU vitamin D (Cholecalciferol) reduces bone turnover markers in HIV-infected patients |
| Q36789908 | Physiologic frailty and fragility fracture in HIV-infected male veterans |
| Q37156878 | Prevalence and Factors Associated with Vitamin D Deficiency and Hyperparathyroidism in HIV-Infected Patients Treated in Barcelona. |
| Q39019753 | Prevalence of vitamin D deficiency in HIV-positive, antiretroviral treatment-naïve patients in a single centre study |
| Q34158739 | Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz |
| Q37987855 | Protease inhibitor monotherapy: what is its role? |
| Q38450420 | Risk factors associated with hypovitaminosis D in HIV/aids-infected adults. |
| Q35898538 | Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines |
| Q36862311 | Safety and Efficacy of High-Dose Daily Vitamin D3 Supplementation in Children and Young Adults Infected With Human Immunodeficiency Virus |
| Q33361817 | Serum total estradiol, but not testosterone is associated with reduced bone mineral density (BMD) in HIV-infected men: a cross-sectional, observational study. |
| Q34538265 | Severe hypovitaminosis D correlates with increased inflammatory markers in HIV infected patients |
| Q57143538 | The Hidden Burden of Fractures in People Living With HIV |
| Q37838799 | The Rapidly Evolving Research on Vitamin D Among HIV-Infected Populations |
| Q35557264 | The effect of aging, nutrition, and exercise during HIV infection |
| Q28483688 | The effect of tenofovir on vitamin D metabolism in HIV-infected adults is dependent on sex and ethnicity |
| Q59352745 | The impact of Middle Eastern Origin, HIV, HCV, and HIV/HCV co-infection in the development of hypovitaminosis D in adults |
| Q38005045 | Therapeutic options for low bone mineral density in HIV-infected subjects |
| Q41659730 | Ultraviolet index and location are important determinants of vitamin D status in people with human immunodeficiency virus |
| Q93153429 | VDR polymorphisms influence immunological response in HIV-1+ individuals undergoing antiretroviral therapy |
| Q37267250 | Validation Protocol of Vitamin D Supplementation in Patients with HIV-Infection. |
| Q40517679 | Vitamin D Deficiency and Metabolism in HIV-Infected and HIV-Uninfected Men in the Multicenter AIDS Cohort Study |
| Q36447199 | Vitamin D Levels, Natural H1N1 Infection and Response to H1N1 Vaccine among HIV-Infected Individuals |
| Q34028199 | Vitamin D and HIV: letting the sun shine in. |
| Q36816930 | Vitamin D and bone loss in HIV |
| Q24613615 | Vitamin D and the anti-viral state |
| Q37145285 | Vitamin D attenuates nucleoside reverse transcriptase inhibitor induced human skeletal muscle mitochondria DNA depletion |
| Q34016783 | Vitamin D deficiency and altered bone mineral metabolism in HIV-infected individuals |
| Q36408936 | Vitamin D deficiency and its association with low bone mineral density, HIV-related factors, hospitalization, and death in a predominantly black HIV-infected cohort |
| Q36200366 | Vitamin D deficiency in HIV-infected and HIV-uninfected women in the United States |
| Q36884537 | Vitamin D in HIV-Infected Patients |
| Q28483647 | Vitamin D inhibits human immunodeficiency virus type 1 and Mycobacterium tuberculosis infection in macrophages through the induction of autophagy |
| Q39591171 | Vitamin D insufficiency and deficiency among HIV-1-infected patients in a tropical setting |
| Q33615509 | Vitamin D insufficiency and subclinical atherosclerosis in non-diabetic males living with HIV |
| Q37518789 | Vitamin D insufficiency may impair CD4 recovery among Women's Interagency HIV Study participants with advanced disease on HAART. |
| Q37492503 | Vitamin D is linked to carotid intima-media thickness and immune reconstitution in HIV-positive individuals |
| Q38663355 | Vitamin D levels and their impact on mineral metabolism in HIV infected patients: an exploratory study |
| Q36506056 | Vitamin D rescues impaired Mycobacterium tuberculosis-mediated tumor necrosis factor release in macrophages of HIV-seropositive individuals through an enhanced Toll-like receptor signaling pathway in vitro |
| Q35245597 | Vitamin D status and its association with morbidity including wasting and opportunistic illnesses in HIV-infected women in Tanzania |
| Q37625118 | Vitamin D status of human immunodeficiency virus-positive patients with advanced liver disease enrolled in the solid organ transplantation in HIV: multi-site study |
| Q35034436 | Vitamin D supplementation and antibacterial immune responses in adolescents and young adults with HIV/AIDS. |
| Q37265049 | Vitamin D-related host genetic variants alter HIV disease progression in children |
| Q38764819 | Vitamin D3 inhibits TNFα-induced latent HIV reactivation in J-LAT cells |
| Q35962186 | Vitamin D3 supplementation in HIV infection: effectiveness and associations with antiretroviral therapy |
| Q36792991 | Vitamin D3 supplementation scheme in HIV-infected patients based upon pharmacokinetic modelling of 25-hydroxycholecalciferol |